HTT and Huntington disease: BioMarin Pharmaceuticals have, however, very recently carried out a study showing that an ASO with sequence (CUG)7 successfully targeted the expanded CAG repeat in mutant Htt mRNA in two different mouse models of HD and that this led to phenotypic improvement [85].